Biliary Tract Cancer Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Biliary Tract Cancer pipeline constitutes 80+ key companies continuously working towards developing 80+ Biliary Tract Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Biliary Tract Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Biliary Tract Cancer Market.

The Biliary Tract Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Biliary Tract Cancer Pipeline Report: https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Biliary Tract Cancer treatment therapies with a considerable amount of success over the years.
• Biliary Tract Cancer companies working in the treatment market are Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others, are developing therapies for the Biliary Tract Cancer treatment
• Emerging Biliary Tract Cancer therapies in the different phases of clinical trials are- Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others are expected to have a significant impact on the Biliary Tract Cancer market in the coming years.
• In December 2023, RenovoRx, a clinical-stage biopharmaceutical company, has chosen Oklahoma University (OU) Health as the initial study center for its Phase III CouGar Trial of RenovoGem for treating bile duct cancer. The trial will evaluate RenovoGem specifically for unresectable locally advanced extrahepatic cholangiocarcinoma (eCCA). This pivotal, randomized trial aims to assess the efficacy and safety of trans-arterial micro-perfusion (TAMP) using the RenovoGem delivery system in combination with gemcitabine and intravenous durvalumab for treating unresectable, locally advanced eCCA.
• In December 2023, The Scottish Medicines Consortium and the UK's National Institute of Health and Care Excellence (NICE) have endorsed AstraZeneca's durvalumab (Imfinzi) as a first-line treatment for adults with advanced biliary tract cancers in England and Scotland. This immunotherapy should be administered alongside the chemotherapy drugs gemcitabine and cisplatin.

Biliary Tract Cancer Overview
Biliary tract cancer, also known as cholangiocarcinoma, is a type of cancer that arises in the bile ducts, which are the tubes that carry bile (a digestive fluid) from the liver to the gallbladder and small intestine.

Get a Free Sample PDF Report to know more about Biliary Tract Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Biliary Tract Cancer Drugs Under Different Phases of Clinical Development Include:
• Keytruda (pembrolizumab): Merck Sharp & Dohme
• Imfinzi (durvalumab): AstraZeneca
• Futibatinib (TAS-120): Taiho Oncology
• Melphalan: Delcath Systems
• E7090 (tasurgratinib): Eisai
• TT-00420: TransThera Sciences (Nanjing)
• ARQ 087 (Derazantinib): Basilea Pharmaceutica
• Lenvima (lenvatinib): Eisai and Merck & Co
• Zanidatamab: Zymeworks and BeiGene
• XmAb20717: Xencor, Inc.
• Nivolumab + DKN-01: Bristol-Myers Squibb/Leap Therapeutics, Inc.
• CTX-009: Compass Therapeutics
• MEDI5752: AstraZeneca
• Brigimadlin: Boehringer Ingelheim
• ZB131: ZielBio, Inc.
• GQ1001: GeneQuantum Healthcare (Suzhou) Co., Ltd.
• BNT141: BioNTech SE
• SO-C101: SOTIO Biotech
• CT-0508: Carisma Therapeutics Inc
• RAIN-32: Rain Oncology Inc
• AVA6000: Avacta Life Sciences Ltd
• DB-1303: DualityBio Inc.

Biliary Tract Cancer Route of Administration
Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Biliary Tract Cancer Molecule Type
Biliary Tract Cancer Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Biliary Tract Cancer Pipeline Therapeutics Assessment
• Biliary Tract Cancer Assessment by Product Type
• Biliary Tract Cancer By Stage and Product Type
• Biliary Tract Cancer Assessment by Route of Administration
• Biliary Tract Cancer By Stage and Route of Administration
• Biliary Tract Cancer Assessment by Molecule Type
• Biliary Tract Cancer by Stage and Molecule Type

DelveInsight's Biliary Tract Cancer Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Biliary Tract Cancer product details are provided in the report. Download the Biliary Tract Cancer pipeline report to learn more about the emerging Biliary Tract Cancer therapies at:
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Biliary Tract Cancer Therapeutics Market include:
Key companies developing therapies for Biliary Tract Cancer are - Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene, and others.

Biliary Tract Cancer Pipeline Analysis:
The Biliary Tract Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Biliary Tract Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Biliary Tract Cancer Treatment.
• Biliary Tract Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Biliary Tract Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Biliary Tract Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Biliary Tract Cancer drugs and therapies-
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Biliary Tract Cancer Pipeline Market Strengths
• The therapeutic landscape in BTCs has expanded considerably in recent years. Combined therapy with chemotherapy, immunotherapy, and modulation of immune checkpoints-mediated signaling pathways are promising strategies.

Biliary Tract Cancer Pipeline Market Opportunities
• Increasing cognizance about different mutations, pathways, and other regimens has changed the focus on curable treatment options with emerging candidates that will lead the growth of the global market.

Scope of Biliary Tract Cancer Pipeline Drug Insight
• Coverage: Global
• Key Biliary Tract Cancer Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others
• Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others
• Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies
• Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer market drivers and Biliary Tract Cancer market barriers

Request for Sample PDF Report for Biliary Tract Cancer Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Biliary Tract Cancer Report Introduction
2. Biliary Tract Cancer Executive Summary
3. Biliary Tract Cancer Overview
4. Biliary Tract Cancer- Analytical Perspective In-depth Commercial Assessment
5. Biliary Tract Cancer Pipeline Therapeutics
6. Biliary Tract Cancer Late Stage Products (Phase II/III)
7. Biliary Tract Cancer Mid Stage Products (Phase II)
8. Biliary Tract Cancer Early Stage Products (Phase I)
9. Biliary Tract Cancer Preclinical Stage Products
10. Biliary Tract Cancer Therapeutics Assessment
11. Biliary Tract Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Biliary Tract Cancer Key Companies
14. Biliary Tract Cancer Key Products
15. Biliary Tract Cancer Unmet Needs
16 . Biliary Tract Cancer Market Drivers and Barriers
17. Biliary Tract Cancer Future Perspectives and Conclusion
18. Biliary Tract Cancer Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Biliary Tract Cancer Market https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Biliary Tract Cancer Epidemiology https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Biliary Tract Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Dermatitis Seborrheic Market https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
DelveInsight's "Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Seborrhoeic Dermatitis, historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastro Intestinal Bleeding Market https://www.delveinsight.com/report-store/gastro-intestinal-bleeding-market
DelveInsight's "Gastro Intestinal Bleeding Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastro Intestinal Bleeding, historical and forecasted epidemiology as well as the Gastro Intestinal Bleeding market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market
DelveInsight's comprehensive report titled "Listeriosis Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Listeriosis. The report presents historical and projected epidemiological data covering incident cases of listeriosis, age-specific cases of listeriosis, gender-specific cases of listeriosis, risk-associated cases of listeriosis, and treated cases of listeriosis.

Point Of Care Glucose Testing Market https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Substance Drug Abuse Market https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.